CN1186056C - medicine for treating hyperosteogeny - Google Patents

medicine for treating hyperosteogeny Download PDF

Info

Publication number
CN1186056C
CN1186056C CNB021195552A CN02119555A CN1186056C CN 1186056 C CN1186056 C CN 1186056C CN B021195552 A CNB021195552 A CN B021195552A CN 02119555 A CN02119555 A CN 02119555A CN 1186056 C CN1186056 C CN 1186056C
Authority
CN
China
Prior art keywords
parts
medicine
radix
rhizoma
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021195552A
Other languages
Chinese (zh)
Other versions
CN1459310A (en
Inventor
黄本云
吴桂芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB021195552A priority Critical patent/CN1186056C/en
Publication of CN1459310A publication Critical patent/CN1459310A/en
Application granted granted Critical
Publication of CN1186056C publication Critical patent/CN1186056C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a medicine for curing hyperosteogeny and rheumatism, in particular, it is a medicine extracted from natural plant. The medicine is a medicament prepared from the following raw materials in parts by weight: 60-80 parts of kusnezoff monkshood root, 0.2-0.5 part of Chinese alangium, 10-20 parts of Tongguan powder, 0.2-0.5 part of radix Anisodi Acutanguli, 5-15 parts of turmeric, 5-15 parts of Japanese yam, 5-15 parts of costus root, 5-15 parts of corydalis tuber, 5-15 parts of broom cypress fruit, 5-15 parts of dracaena cochinchinensis, 5-15 parts of erythrina indica, 4-7 parts of rhizoma paridis, 10-20 parts of cherokee rose fruit, 5-15 parts of cynanchum root, 5-15 parts of camphorwood and. Acute and chronic toxicity tests prove that the medicine has no toxic or side effect. The medicine of the invention is mainly used for treating various hyperosteogeny, rheumatoid arthritis, scapulohumeral periarthritis, sciatica, gout and lumbago.

Description

Medicine for treating osteoproliferation
The present invention relates to a kind of treatment hyperosteogeny and rheumatismal medicine, especially with the medicine of extracted form natural plant.
Chinese patent application CN1073099A (application number 91111593) discloses a kind of " manufacture method of treatment hyperosteogeny pill ", it is characterized in that used herbal species and prescription are: Radix Angelicae Sinensis 5.0~9.0g, Radix Achyranthis Bidentatae 5.0~9.0g, give birth to Rhizoma Chuanxiong 50.0~80.0g, Radix Saposhnikoviae 25.0g, Radix Angelicae Dahuricae 50.0g, Radix Paeoniae Rubra 25.0~30.0g, Rhizoma Gastrodiae 25.0~30.0g, Flos Caryophylli 10.0~15.0g, Fructus Chaenomelis 50.0~60.0g, Rhizoma Et Radix Notopterygii 25.0~30.0g, Rhizoma Zingiberis 25.0~30.0g, Olibanum 10.0~15.0g, Myrrha 12.5~15.0g, Radix Aucklandiae (Radix Vladimiriae) 12.5~15.0g, Radix Aconiti Kusnezoffii 25.0~30.0g, Lignum Aquilariae Resinatum 12.5~15.0g, Cortex Cinnamomi 25.0~30.0g, its manufacturing process is for carrying out the infusion dried with Chinese medicine earlier, again through pulverizing, sieve, add sweet mixing and molding.
Chinese patent application CN1163755B (patent No. ZL96103823) discloses a kind of " injections of Chinese medicine of treatment rheumatic arthritis, hyperosteogeny and preparation method thereof ", it is characterized in that it is to be made by the following weight Chinese medicinal raw materials: Radix Paeoniae Alba 40-55 part Rhizoma Et Radix Notopterygii 10-25 part Rhizoma Chuanxiong 20-35 part Herba Asari 1-2 part.
The object of the present invention is to provide a kind of treatment hyperosteogeny, rheumatismal pure natural medical.
Medicine for treating osteoproliferation of the present invention is the medicament of being made by the following weight proportion raw material:
Radix Aconiti Kusnezoffii 60-80, Radix Alangii 0.2-0.5, TONGGUAN FEN 10-20, Radix Anisodi Acutanguli 0.2-0.5, Rhizoma Curcumae Longae 5-15, Prospiroboli joannsi 5-15, Radix Aucklandiae 5-15, Rhizoma Corydalis 5-15, Herba Lespedezae Cuneatae 5-15, Rhizoma Polygoni Paleachi 5-15, erythrina indica 5-15, Rhizoma Paridis 4-7, Fructus Rosae Laevigatae 10-20, Radix Heraclei Rapulae 5-15, Lignum cinnamomi camphorae 5-15, Radix Salviae Miltiorrhizae 10-20.
Also can add its weight proportion of Herba Chloranthi Henryi (Herba Choranthi seu Lysimachiae) in above-mentioned medicament is 5-10, and its weight proportion of Pachysandra axillaris Franch. is 5-10.
Medicine of the present invention can be made said dosage form on any pharmaceutics.
Medicine of the present invention proves through acute and chronic toxicity test, has no side effect.Medicine of the present invention has the effect of relaxing muscles and tendons and activating QI and blood in the collateral, blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, anti-inflammation detumescence, cure mainly all types of hyperosteogenys, rheumatic arthritis, rheumatoid, scapulohumeral periarthritis, sciatica, gout, lumbago, can treat also that wind myositis, cold hand and foot, bone tuberculosis, cerebral hemorrhage, cerebral infarction sequela, apoplectic hemiplegia, intervertebral disk hernia are deviate from, disease such as wound in the old.Through clinical verification, total effective rate reaches more than 90%.
Embodiment:
Get Radix Alangii 0.3 gram, TONGGUAN FEN 14 grams, Radix Anisodi Acutanguli 0.5 gram, Rhizoma Curcumae Longae 8 grams, Prospiroboli joannsi 7 grams, the Radix Aucklandiae 6 grams, Rhizoma Corydalis 10 grams, Herba Lespedezae Cuneatae 5 grams, Rhizoma Polygoni Paleachi 6 grams, erythrina indica 9 grams, Rhizoma Paridis 5 grams, Fructus Rosae Laevigatae 12 grams, Radix Heraclei Rapulae 10 grams, Lignum cinnamomi camphorae 8 grams, Radix Salviae Miltiorrhizae 15 grams.Clean, section is dried, and it is stand-by to make powdery.
Get Radix Aconiti Kusnezoffii 62 grams that dig autumn, boiled 2-3 hour with boiled water, section is dried, and breaks into powder behind the husky or fried bubble of reuse, adds above-mentioned stand-by medicated powder and mixes thoroughly and get final product.

Claims (1)

1, a kind of medicine for treating osteoproliferation is characterized in that it being the medicament of being made by the following weight proportion raw material: Radix Aconiti Kusnezoffii 60-80, Radix Alangii 0.2-0.5, TONGGUAN FEN 10-20, Radix Anisodi Acutanguli 0.2-0.5, Rhizoma Curcumae Longae 5-15, Prospiroboli joannsi 5-15, Radix Aucklandiae 5-15, Rhizoma Corydalis 5-15, Herba Lespedezae Cuneatae 5-15, Rhizoma Polygoni Paleachi 5-15, erythrina indica 5-15, Rhizoma Paridis 4-7, Fructus Rosae Laevigatae 10-20, Radix Heraclei Rapulae 5-15, Lignum cinnamomi camphorae 5-15, Radix Salviae Miltiorrhizae 10-20.
CNB021195552A 2002-05-24 2002-05-24 medicine for treating hyperosteogeny Expired - Fee Related CN1186056C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021195552A CN1186056C (en) 2002-05-24 2002-05-24 medicine for treating hyperosteogeny

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021195552A CN1186056C (en) 2002-05-24 2002-05-24 medicine for treating hyperosteogeny

Publications (2)

Publication Number Publication Date
CN1459310A CN1459310A (en) 2003-12-03
CN1186056C true CN1186056C (en) 2005-01-26

Family

ID=29426810

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021195552A Expired - Fee Related CN1186056C (en) 2002-05-24 2002-05-24 medicine for treating hyperosteogeny

Country Status (1)

Country Link
CN (1) CN1186056C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100337669C (en) * 2005-08-17 2007-09-19 袁银龙 Externally applied medicine for curing pain and process for preparing the same
CN101884652A (en) * 2010-07-19 2010-11-17 唐宇龙 Medicament for treating osteoproliferation
CN102512505B (en) * 2011-11-29 2013-10-02 郑星有 Chinese patent medicine for treating bone spur
CN103768200B (en) * 2014-01-09 2016-04-20 汤伟杰 A kind of Chinese herbal medicine granule for the treatment of hyperosteogeny and preparation method thereof

Also Published As

Publication number Publication date
CN1459310A (en) 2003-12-03

Similar Documents

Publication Publication Date Title
CN1899535A (en) Method for preparing dermopathic blood toxic capsule
CN1204523A (en) Prescription of dispelling wind and strengthening bone wine and preparation method
CN1278446A (en) Chinese medicinal composition for cerebrovascular disease, rheumatism and rheumatoid disease
CN111840383A (en) Targeted spray moxibustion composition for treating rheumatic arthritis and preparation and use methods thereof
CN103316192B (en) Traditional Chinese medicine foot-bathing liquid for treating lumbocrural pain and preparation method thereof
CN102309723A (en) Traditional Chinese medicine composition for treating arthralgia and preparation method of ointment thereof
CN100366278C (en) Method for preparing traditional Chinese medicine for treating rheumatism and rheumatoid disease, and said medicine thereby
CN1129130A (en) Medicament for treatment of cervical spondylopathy
CN1186056C (en) medicine for treating hyperosteogeny
CN100381146C (en) Traditional Chinese medicine for treating rheumatism
CN101284084A (en) Externally used Chinese medicine for curing hyperosteogeny and protrusion of lumbar intervertebral discs
CN103341013B (en) A kind of Chinese medicine for the treatment of lumbago and skelalgia
CN100396316C (en) Chinese medicine capsule for treating protrusion of intervertebral disc and hyperosteogeny
CN101099848A (en) Traditional Chinese medicine powder agent for treating rheumatic arthritis, rheumatoid arthritis and ostealgia
CN1071123C (en) Preparatory Chinese-medicine for treatment of hepatitis and hepatoascites
CN101167864A (en) Traditional Chinese medicinal formula for treating hyperosteogeny
CN101337049A (en) Production method of pills for treating rheumatoid, rheumatism and infantile paralysis
CN1063650C (en) Chinese medicinal pill for curing rheumatism and rheumatoid disease and its preparation method
CN1333026A (en) Medicine for treating hyperplasia of mammary glands
CN1054052C (en) Comedo-elimination preparation
CN1122520C (en) Osteanaphysis capsule for treating femoral head necrosis
CN1698801A (en) Capsule for treating hemiplegia and rheumatism
CN1457826A (en) Capsule for killing pain and recovery
CN1141953C (en) Family handed traditional Chinese medicine recipe of osteomyelitis treatment
CN1214920A (en) Gucixiao pill for removing spur

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20081212

Address after: No. 6 Fenghuang Road, Yunnan, Yuxi

Patentee after: Wu Guifang

Address before: No. 6 West Station Road, Yunnan, Yuxi

Patentee before: Huang Benyun

ASS Succession or assignment of patent right

Owner name: WU GUIFANG

Free format text: FORMER OWNER: HUANG BENYUN

Effective date: 20081212

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050126

Termination date: 20170524

CF01 Termination of patent right due to non-payment of annual fee